Bristol-Myers Opdivo/Yervoy Combo Meets Main Endpoint in NSCLC Study

Date : 10/22/2019 @ 12:59PM
Source : Dow Jones News
Stock : Bristol Myers Squibb Co (BMY)
Quote : 63.82  -0.12 (-0.19%) @ 12:01AM
After Hours
Last Trade
Last $ 63.88 ▲ 0.06 (0.09%)

Bristol-Myers Opdivo/Yervoy Combo Meets Main Endpoint in NSCLC Study

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart

2 Months : From Oct 2019 to Dec 2019

Click Here for more Bristol Myers Squibb Charts.

By Colin Kellaher


Bristol-Myers Squibb Co. (BMY) Tuesday said a phase 3 study evaluating its cancer drug Opdivo plus low-dose Yervoy combined with chemotherapy met its primary endpoint of superior overall survival for the first-line treatment of advanced non-small cell lung cancer.

The New York biopharmaceutical company said the study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy versus chemotherapy alone.

Non-small cell lung cancer, or NSCLC, is the most common type of lung cancer, accounting for up to 85% of diagnoses.

Bristol-Myers said it plans to complete a full evaluation of the study results, which it said build on the benefit the combination of Opdivo plus Yervoy has previously shown in other cancers.


Write to Colin Kellaher at


(END) Dow Jones Newswires

October 22, 2019 08:44 ET (12:44 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest BMY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.